PRO-OXAZEPAM DIN 00497762
Health Canada record
| Active ingredient(s) | OXAZEPAM 15 MG |
|---|---|
| Dosage form | Tablet |
| Route | Oral |
| Schedule | TARGETED SUBSTANCES (CDSA IV) |
| Class | Human |
| ATC | N05BA04 OXAZEPAM |
| Original market date | 31-Dec-1980 |
| Current status date | 19-Jul-2023 |
| Source | Health Canada DPD |
Establishment licence of the holder
Pro Doc Limitée — licence 100182, currently licensed, last inspection rating C (2025-08-11).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing OXAZEPAM
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 00402737 | APO-OXAZEPAM | APOTEX INC | Tablet | OXAZEPAM 30 MG | Marketed |
| 00402745 | APO-OXAZEPAM | APOTEX INC | Tablet | OXAZEPAM 15 MG | Marketed |
| 00402680 | APO-OXAZEPAM | APOTEX INC | Tablet | OXAZEPAM 10 MG | Marketed |
| 00497770 | PRO-OXAZEPAM | PRO DOC LIMITEE | Tablet | OXAZEPAM 30 MG | Marketed |
| 00497754 | PRO-OXAZEPAM | PRO DOC LIMITEE | Tablet | OXAZEPAM 10 MG | Marketed |
| 00568406 | RIVA-OXAZEPAM | LABORATOIRE RIVA INC. | Tablet | OXAZEPAM 15 MG | Marketed |
| 00568392 | RIVA-OXAZEPAM | LABORATOIRE RIVA INC. | Tablet | OXAZEPAM 10 MG | Marketed |
| 00568414 | RIVA-OXAZEPAM | LABORATOIRE RIVA INC. | Tablet | OXAZEPAM 30 MG | Marketed |
| 02247179 | BIO-OXAZEPAM | BIOMED PHARMA | Tablet | OXAZEPAM 30 MG | Cancelled Post Market |
| 02247177 | BIO-OXAZEPAM | BIOMED PHARMA | Tablet | OXAZEPAM 10 MG | Cancelled Post Market |
| 02247178 | BIO-OXAZEPAM | BIOMED PHARMA | Tablet | OXAZEPAM 15 MG | Cancelled Post Market |
| 00500852 | NOVOXAPAM TAB 10MG | NOVOPHARM LIMITED | Tablet | OXAZEPAM 10 MG | Cancelled Post Market |
| 00496529 | NOVOXAPAM TAB 15MG | NOVOPHARM LIMITED | Tablet | OXAZEPAM 15 MG | Cancelled Post Market |
| 00496537 | NOVOXAPAM TAB 30MG | NOVOPHARM LIMITED | Tablet | OXAZEPAM 30 MG | Cancelled Post Market |
| 02232721 | OXAZEPAM 10MG TABLETS | LABORATOIRES CONFAB INC | Tablet | OXAZEPAM 10 MG | Cancelled Pre Market |
| 02232727 | OXAZEPAM 15MG TABLETS | LABORATOIRES CONFAB INC | Tablet | OXAZEPAM 15 MG | Cancelled Pre Market |
| 02232732 | OXAZEPAM 30MG TABLETS | LABORATOIRES CONFAB INC | Tablet | OXAZEPAM 30 MG | Cancelled Pre Market |
| 00483915 | OXAZEPAM TABLETS 15MG | D.C. LABS LIMITED | Tablet | OXAZEPAM 15 MG | Cancelled Post Market |
| 00483907 | OXAZEPAM TABLETS 30MG | D.C. LABS LIMITED | Tablet | OXAZEPAM 30 MG | Cancelled Post Market |
| 00414263 | OXPAM | BIOMED PHARMA | Tablet | OXAZEPAM 30 MG | Dormant |
| 00414255 | OXPAM | BIOMED PHARMA | Tablet | OXAZEPAM 15 MG | Dormant |
| 00414247 | OXPAM | BIOMED PHARMA | Tablet | OXAZEPAM 10 MG | Dormant |
| 00726362 | PMS-OXAZEPAM TAB 10MG | PHARMASCIENCE INC | Tablet | OXAZEPAM 10 MG | Cancelled Post Market |
| 00726370 | PMS-OXAZEPAM TAB 15MG | PHARMASCIENCE INC | Tablet | OXAZEPAM 15 MG | Cancelled Post Market |
| 00726389 | PMS-OXAZEPAM TAB 30MG | PHARMASCIENCE INC | Tablet | OXAZEPAM 30 MG | Cancelled Post Market |
| 00295698 | SERAX TAB 15MG | WYETH LTD. | Tablet | OXAZEPAM 15 MG | Cancelled Post Market |
| 00231363 | SERAX TAB 30MG | WYETH LTD. | Tablet | OXAZEPAM 30 MG | Cancelled Post Market |
| 02043653 | SERAX TABLETS 10MG | WYETH-AYERST CANADA INC. | Tablet | OXAZEPAM 10 MG | Cancelled Post Market |
| 02043661 | SERAX TABLETS 15MG | WYETH-AYERST CANADA INC. | Tablet | OXAZEPAM 15 MG | Cancelled Post Market |
| 02043688 | SERAX TABLETS 30MG | WYETH-AYERST CANADA INC. | Tablet | OXAZEPAM 30 MG | Cancelled Post Market |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 27966 | 2022-04-13 | New Drug Submission (NDS) | Administrative: Licensing Agreement Between Two Companies |
International API supply for OXAZEPAM
3 valid EDQM Certificates of Suitability from 3 holders. 5 active FDA Drug Master Files.
Request a quote for PRO-OXAZEPAM